ClinicalTrials.gg
Not yet recruitingNCT07731100Updated Jul 28, 2026

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

A Phase 1 interventional study of Prifetrastat in Healthy Adults, sponsored by Pfizer. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to assess the effect of food (high-fat, high-calorie meal) on the total and peak drug exposure of the planned to be marketed tablet formulation of prifetrastat.

This study is seeking participants who are:

- Healthy males and females of nonchildbearing potential ≥18 years of age at screening

The participants will receive study medicine prifetrastat as a single tablet by mouth at study clinic under fed or fasted condition. After at least 14 days, they will receive another single tablet of prifetrastat by mouth under fasted or fed condition. The sequence of conditions (fed or fasted first) will be randomized.

The results of this study will enable data-driven guidance regarding food intake for participants enrolled in clinical studies of prifetrastat as well as patients receiving prifetrastat post-marketing. Participants will remain in clinic for about 21 days and have one follow up contact.

02

Conditions studied

  • Healthy Adults

Keywords

  • Prifetrastat
  • Food Effect
  • PF-07248144
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of nonchildbearing potential and males ≥18 years of age at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs.
  • (BMI) of 18-32 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria

  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention
  • Any prior use of epigenetic modifying agents.
  • Current use or anticipated need for food or drugs that are known moderate or strong inducers or inhibitors of CYP2C9 or , including their administration within 14 days plus 5 half-lives of the inducers or 14 days or 5 half lives (whichever is longer) for the inhibitors of CYP2C9 or CYP3A4, prior to first dose of study intervention, during the treatment period, and within 6 days after the last dose of prifetrastat.
  • Proton pump inhibitors must be discontinued at least 14 days prior to the first dose of study medication and throughout treatment period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Sequence AB

    Period 1 (Treatment A) : PF-07248144 single dose following an overnight fast Period 2 (Treatment B): PF-07248144 single dose following a high-fat, high-calorie meal Treatments A and B will be separated with a washout of at least 14 days

    Drug: Prifetrastat

  • Experimental
    Sequence BA

    Period 1 (Treatment B): PF-07248144 single dose following a high-fat, high-calorie meal Period 2 (Treatment A): PF-07248144 single dose following an overnight fast Treatments B and A will be separated with a washout of at least 14 days

    Drug: Prifetrastat

Interventions

  • Participants will receive Prifetrastat as a single dose, oral tablet on Day 1 of Period 1 and Day 1 of Period 2 with a washout period between two doses

    Also known as: PF-07248144

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for Prifetrastat

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose

  2. Area under the concentration-time curve from time zero to time of last measurable concentration (AUClast) for Prifetrastat

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose

  3. Maximum observed plasma concentration (Cmax) for Prifetrastat

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events

    Time frame: Up to 28 to 35 days post last study intervention dose

  2. Number of participants with laboratory test abnormalities

    Time frame: Up to 28 to 35 days post last study intervention dose

  3. Number of participants with vital signs values meeting categorical summarization criteria

    Time frame: Up to 28 to 35 days post last study intervention dose

  4. Number of participants with clinically significant physical examination abnormalities

    Time frame: Up to 28 to 35 days post last study intervention dose

  5. Number of participants with treatment emergent clinically significant abnormal electrocardiogram (ECG) measurements

    Time frame: Up to 28 to 35 days post last study intervention dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Sep 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 28, 2026
StartEst.
Jul 24, 2026
Primary completionEst.
Sep 10, 2026
CompletionEst.
Oct 2, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731100
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jul 24, 2026 (estimated)
Primary completion
Sep 10, 2026 (estimated)
Completion
Oct 2, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prifetrastat

Start the discussion